drugset
drugset / Trial / NCT03744403

A Study of CS1001 in Subjects with Advanced Solid Tumors

NCT03744403 ↗

Phase 1 Completed 24 enrolled CStone Pharmaceuticals
NaSingle-groupOpen-labelTreatment

Summary

This is a phase I, open-label, multiple-dose, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics and anti-tumor activity of CS1001 in subjects with advanced solid tumors.

Timeline

Start
2018-12-04
Primary completion
2020-10-31
Completion
2021-07-21

Drugs

EvaluationDrugModalityDoseRoute
Subject Sugemalimab Monoclonal antibody — —

Indications

cancer